Source: https://www.fr.com/jonathan-e-singer/
Timestamp: 2019-04-25 08:52:05+00:00

Document:
Mr. Singer is a principal in the Firm’s San Diego Office and heads the Firm’s life sciences litigation practice. Mr. Singer appears regularly as lead counsel in his matters and handles all aspects of litigation, including leading jury and bench trials, trying cases to administrative and arbitration panels and conducting briefing and arguments before the Courts of Appeals and the PTAB. Mr. Singer is annually named one of the nation’s finest life sciences trial attorneys and is an expert in proceedings under the Hatch-Waxman Act. His clients consistently praise his innovative and ground-breaking work and over the past two decades, he has successfully handled dozens of cases covering all aspects of the life sciences. In addition to his courtroom work, Mr. Singer regularly teaches life sciences trial and patent practice courses in the U.S. and Europe.
Course faculty member, “Biotechnology: Patent Prosecution, Licensing, Litigation, and Hatch-Waxman,” Patent Resources Group, Inc.
Allergan, Inc. v. Sandoz., Inc. (E.D. Tx.; D. N.J.): Trial counsel for Allergan in actions over Allergan’s eye pressure lower medication COMBIGAN®. Injunction entered against generic entry in EDTX in 2016. On appeal, Federal Circuit affirmed validity of asserted patents but reversed on infringement; thereafter, secured preliminary injunction against generic launch in DNJ. Appeal pending.
Athena Diagnostics, et al v. Mayo Collaborative Services, et al (D.Mass.): District court and appellate counsel for Mayo defendants in action over Mayo’s test for Myasthenia Gravis. Judgment on the pleadings under Section 101 granted for Mayo. Affirmed on appeal.
Coherus Biosciences, Inc. v. AbbVie Biotechnology Ltd. (PTAB): PTAB counsel for petitioner Coherus. Argued and obtained first ever invalidity ruling on patents covering AbbVie’s blockbuster drug, HUMIRA®. Case settled on appeal.
Gilead Sciences, Inc. v. Merck & Co, Inc., et al, (N.D.Cal.): Trial counsel for Gilead against Merck in action over Gilead’s revolutionary Hepatitis C drugs, HARVONI® and SOVALDI®. After jury found liability against Gilead and awarded $200 million to Merck, led bench trial and hearings that resulted in district court setting aside the judgment for unclean hands. Affirmed on appeal. Read about this historic win here and here.
Idenix Corp. v. Gilead Sciences, Inc. (D.Del.): Trial counsel for Gilead in further action over Gilead’s Hepatitis C drugs HARVONI® and SOVALDI® by Merck subsidiary, Idenix. After jury found liability against Gilead and awarded damages in excess of $2 billion, argued JMOL proceedings that resulted in district court setting aside the judgment for lack of enablement of the patent-in-suit. Appeal pending.
Gilead Sciences, Inc. v. AbbVie Biotechnology Ltd. (D.Del.): District court counsel for Gilead in action over Gilead’s Hepatitis C drugs HARVONI® and SOVALDI®. After favorable Markman ruling, case settled with business arrangement.
Aptalis Pharmatech, Inc., et al v. Apotex, Inc. et al (D.Del.): Trial counsel for plaintiffs in action over skeletal muscle relaxant drug AMRIX. Injunction secured against generic entry. After remand from Federal Circuit on infringement issues, case settled with business arrangement.
Allergan, Inc. v. Sandoz Inc., et al (E.D.Tx.): Trial counsel for plaintiff in Hatch-Waxman action over ANDAs for glaucoma drug LUMIGAN® 0.01. Injunction entered against generic entry in January 2014. Injunction affirmed on appeal.
Cephalon, Inc., et al v. Mylan Labs, et al (D. Del.): Trial counsel for plaintiffs in Hatch-Waxman action over ANDA for breakthrough pain drug FENTORA®. Injunction entered against generic entry in July 2013. Case resolved on appeal with business arrangement.
Roche Palo Alto, et al v. Lupin, Ltd., et al (D.N.J.): Trial counsel for plaintiffs in Hatch-Waxman action over ANDA for angina drug RANEXA®; after three-week bench trial in May 2013, case settled with Lupin agreeing to forestall entry until three months before patent expiry.
Prometheus Laboratories v. Mayo Collaborative Services, et al (S.D.Cal.): District court and appellate counsel for defendants in patent infringement action over metabolite assays for thiopurine drugs. Argued and secured summary judgment of invalidity under 35 U.S.C. § 101. After reversal at Federal Circuit Court of Appeals, Supreme Court of the United States reversed appellate court at __ U.S. __, 132 S.Ct. 1289 (2012). Widely recognized as most important patent case of 2012.
Mayo Clinic, et al v. Peter Elkin (D.Minn.): Trial counsel for Mayo Clinic in trade secret case regarding natural language processing software. Jury verdict in favor of Mayo on willful trade secret misappropriation, intentional interference with contractual relations and other claims. Verdict affirmed at 2013 WL 4516191 (8th Cir. 2013).
Eurand, Inc. v. Impax Labs (In re Cyclobenzaprine) (D. Del.): District court and appellate counsel for plaintiffs in action for enforcement of settlement of Hatch-Waxman litigation. Secured judgment in favor of plaintiffs restraining defendant from launching product in February 2012. Affirmed at 504 Fed. Appx. 900 (Fed. Circ. 2013).
Allergan, Inc. v. Barr Labs, Inc. (D. Del.): Trial and appellate counsel for plaintiffs in Hatch-Waxman action over ANDAs for glaucoma drug LUMIGAN®. Injunction entered against generic entry in September 2011. Injunction affirmed at 501 Fed. Appx. 965 (Fed. Circ. 2013).
Allergan, Inc. v. Sandoz, Inc., et al (E.D.Tx.): Trial counsel for plaintiff in Hatch-Waxman actions over ANDAs for glaucoma drug COMBIGAN®. Injunction entered against generic entry in August 2011. Injunction affirmed at 726 F.3d.1286 (Fed. Cir. 2013).
In re Cyclobenzaprine Hydrochloride Extended Release Litigation (D. Del.): Trial and appellate counsel for plaintiffs in Hatch-Waxman actions over ANDAs for skeletal muscle relaxant AMRIX®. After verdict of obviousness, secured temporary restraining order against “launch at risk” by defendant Mylan. Secured reversal at Federal Circuit Court of Appeals at 676 F.3d 1063 (Fed. Cir. 2012).
Allergan, Inc. v. Akorn, Inc., et al (D. Del.): District court counsel for plaintiff in Hatch-Waxman action over ANDA for ocular pain drug ACUVAIL®. Case amicably settled.
Allergan, Inc. v. Akorn, Inc, et al (E.D.Tx.): District court counsel for plaintiff in patent infringement actions over generic versions of ocular pain drug ACULAR® LS. Cases amicably settled.
Cephalon, Inc., et al v. Watson Pharmaceuticals, Inc., et al (D. Del.): Trial counsel for plaintiffs in Hatch-Waxman action over ANDAs for breakthrough pain drug FENTORA®. Injunction entered against generic entry at 769 F.Supp.2d 761 (D. Del.) in April 2011. Affirmed on appeal.
In re Brimonidine Patent Litigation, MDL No. 1866 (D. Del.): Trial and appellate counsel for Allergan in multi-district litigation regarding ANDAs for glaucoma drugs, ALPHAGAN P .15% and ALPHAGAN® P .1%. Injunction entered against generic entry in October 2009. Injunction affirmed at 643 F.3d 1366 (Fed. Cir. 2011).

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 § 101
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.